For immediate release |
19 November 2018 |
RNS REACH
Evgen Pharma plc
("Evgen" or "the Company")
Investor Presentation in Manchester
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Steve Franklin, the Company's CEO, will be presenting tomorrow evening at a ShareSoc Growth Company Seminar in Manchester.
In the presentation, Steve Franklin will outline the Company's proprietary technology and describe its two on-going Phase II trials in metastatic breast cancer and subarachnoid haemorrhage. He will also answer any questions from investors.
The ShareSoc event, which is primarily for private investors, starts at 5.30pm on 20 November 2018 and is being held at the DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester M1 3DG.
Further details of the event, along with a registration form, are available at this link:
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-20-november-2018/
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com |
c/o +44 (0) 20 7466 5000 |
|
|
Buchanan Mark Court, Sophie Wills, Tilly Abraham |
+44 (0) 20 7466 5000 |
|
|
Northland Capital Partners Limited Matthew Johnson, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking) |
+44 (0) 20 3861 6625 |
WG Partners LLP Nigel Barnes, Claes Spång |
+44 (0) 20 3705 9330 |
| |
|
|
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
